Enfortumab vedotin (EV) as monotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of stage I of a phase 2 trial.

Details

Language :

English

ISSN :

0732183X

Volume :

42

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

175073832

Full Text :

https://doi.org/10.1200/JCO.2024.42.4_suppl.152